Stock Scorer

Jazz Pharmaceuticals plc (JAZZ)

Jazz Pharmaceuticals plc reported revenue of 1.2B USD for the quarter ending 30 June 2026, up 15.5% from 1B a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 1.2B +15.5%
Gross Profit Q4 '20 · ending 31 December 2020 611.1M +12.9%
Operating Income Q2 '26 · ending 30 June 2026 248.2M —
Net Income Q2 '26 · ending 30 June 2026 192.8M —
Operating Cash Flow Q2 '26 · ending 30 June 2026 415.7M +368.1%
Free Cash Flow Q2 '26 · ending 30 June 2026 397.6M +423.8%
Shares Outstanding Q2 '26 · ending 30 June 2026 69.4M +13.8%
EPS Q2 '26 · ending 30 June 2026 14.63 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 4.3B-430.2M-356.1M1.3B
20242024-12-31 4.1B716.6M560.1M1.4B
20232023-12-31 3.8B578.6M414.8M1.1B
20222022-12-31 3.7B-65.5M-224.1M1.2B
20212021-12-31 3.1B170.3M-329.7M750.9M
20202020-12-31 2.4B378.1M238.6M884.6M
20192019-12-31 2.2B532.4M523.4M736.3M
20182018-12-31 1.9B614.8M447.1M778.5M
20172017-12-31 1.6B528.8M487.8M664.1M
20162016-12-31 1.5B591.7M396.8M582.7M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-301.2B
Q1 '262026-03-311.1B
Q4 '252025-12-311.2B
Q3 '252025-09-301.1B
Q2 '252025-06-301B
Q1 '252025-03-31897.8M
Q4 '242024-12-311.1B
Q3 '242024-09-301.1B
Q2 '242024-06-301B
Q1 '242024-03-31902M
Q4 '232023-12-311B
Q3 '232023-09-30972.1M
Q2 '232023-06-30957.3M
Q1 '232023-03-31892.8M
Q4 '222022-12-31972.1M
Q3 '222022-09-30940.7M
Q2 '222022-06-30932.9M
Q1 '222022-03-31813.7M
Q4 '212021-12-31896.7M
Q3 '212021-09-30838.1M

Gross Profit Quarterly

PeriodEndingGross Profit
Q4 '202020-12-31611.1M
Q3 '202020-09-30554.9M
Q2 '202020-06-30530.2M
Q1 '202020-03-31501.5M
Q4 '192019-12-31541.2M
Q3 '192019-09-30500.9M
Q2 '192019-06-30495.7M
Q1 '192019-03-31469.8M
Q4 '182018-12-31441M
Q3 '182018-09-30438.6M
Q2 '182018-06-30461.4M
Q1 '182018-03-31406.9M
Q4 '172017-12-31404.8M
Q3 '172017-09-30376.8M
Q2 '172017-06-30361M
Q1 '172017-03-31348.6M
Q4 '162016-12-31359M
Q3 '162016-09-30347.3M
Q2 '162016-06-30355.1M
Q1 '162016-03-31310.5M

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30248.2M
Q1 '262026-03-31336.6M
Q3 '252025-09-3057.5M
Q2 '252025-06-30-686.4M
Q1 '252025-03-31-55.9M
Q4 '242024-12-31190.8M
Q3 '242024-09-30260.2M
Q2 '242024-06-30199.4M
Q1 '242024-03-3166.2M
Q4 '232023-12-31122.5M
Q3 '232023-09-30172.4M
Q2 '232023-06-30157.6M
Q1 '232023-03-31126.1M
Q3 '222022-09-3024.8M
Q2 '222022-06-3085.5M
Q1 '222022-03-3187.5M
Q4 '212021-12-3149.4M
Q3 '212021-09-3028.4M
Q2 '212021-06-30-69.6M
Q1 '212021-03-31162.1M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30192.8M
Q1 '262026-03-31293.1M
Q4 '252025-12-31203.4M
Q3 '252025-09-30251.4M
Q2 '252025-06-30-718.5M
Q1 '252025-03-31-92.5M
Q4 '242024-12-31191.1M
Q3 '242024-09-30215.1M
Q2 '242024-06-30168.6M
Q1 '242024-03-31-14.6M
Q4 '232023-12-3194.2M
Q3 '232023-09-30146.8M
Q2 '232023-06-30104.4M
Q1 '232023-03-3169.4M
Q4 '222022-12-31-240.7M
Q3 '222022-09-30-19.6M
Q2 '222022-06-3034.7M
Q1 '222022-03-311.6M
Q4 '212021-12-31-35.4M
Q3 '212021-09-30-52.8M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30415.7M
Q1 '262026-03-31408.2M
Q4 '252025-12-31362.5M
Q3 '252025-09-30474.7M
Q2 '252025-06-3088.8M
Q1 '252025-03-31429.8M
Q4 '242024-12-31398.6M
Q3 '242024-09-30398.7M
Q2 '242024-06-30331.4M
Q1 '242024-03-31267.2M
Q4 '232023-12-31167.3M
Q3 '232023-09-30307.2M
Q2 '232023-06-30296.8M
Q1 '232023-03-31320.7M
Q4 '222022-12-31342M
Q3 '222022-09-30418M
Q2 '222022-06-30303M
Q1 '222022-03-31209M
Q4 '212021-12-31177.8M
Q3 '212021-09-30274.1M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30397.6M
Q1 '262026-03-31388.5M
Q4 '252025-12-31345.8M
Q3 '252025-09-30459.4M
Q2 '252025-06-3075.9M
Q1 '252025-03-31415.9M
Q4 '242024-12-31385.3M
Q3 '242024-09-30388M
Q2 '242024-06-30324.3M
Q1 '242024-03-31260.3M
Q4 '232023-12-31157.2M
Q3 '232023-09-30302.9M
Q2 '232023-06-30291M
Q1 '232023-03-31316.9M
Q4 '222022-12-31332.6M
Q3 '222022-09-30413.1M
Q2 '222022-06-30290.8M
Q1 '222022-03-31196.7M
Q4 '212021-12-31167.8M
Q3 '212021-09-30265.7M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-3069.4M
Q1 '262026-03-3166.1M
Q3 '252025-09-3061.6M
Q2 '252025-06-3061.2M
Q1 '252025-03-3161M
Q3 '242024-09-3063.2M
Q2 '242024-06-3069.6M
Q1 '242024-03-3162.5M
Q3 '232023-09-3071.3M
Q2 '232023-06-3073.5M
Q1 '232023-03-3173.8M
Q3 '222022-09-3062.8M
Q2 '222022-06-3063.4M
Q1 '222022-03-3162.9M
Q3 '212021-09-3061.3M
Q2 '212021-06-3059.4M
Q1 '212021-03-3158.4M
Q3 '202020-09-3056.2M
Q2 '202020-06-3055.9M
Q1 '202020-03-3156M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-3014.63
Q1 '262026-03-310.11
Q4 '252025-12-31-5.84
Q3 '252025-09-30-6.16
Q2 '252025-06-30-6.82
Q1 '252025-03-317.41
Q4 '242024-12-318.70
Q3 '242024-09-307.11
Q2 '242024-06-305.83
Q1 '242024-03-314.86
Q4 '232023-12-316.13
Q3 '232023-09-300.86
Q2 '232023-06-30-1.59
Q1 '232023-03-31-2.56
Q4 '222022-12-31-3.57
Q3 '222022-09-30-0.27
Q2 '222022-06-30-0.82
Q1 '222022-03-31-7.48
Q4 '212021-12-31-5.42
Q3 '212021-09-30-2.55